检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Lebrikizumab improvement in itch reduction at 52 weeks in patients with moderate-to-severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials

Gil Yosipovitch,Peter Lio,David Rosmarin,Franz Legat,Jose Manuel Carrascosa,Eric Meskimen,Marta Casillas,Evangeline Pierce,Zhuqing Liu,Jinglin Zhong,Sonja Staender

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2023）

引用 0|浏览10
暂无评分
关键词
lebrikizumab improvement,itch reduction,moderate-to-severe
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要